Edition

Colman Taylor

2

Articles

0

Comments

Post-doctoral Research Fellow, The George Institute; Conjoint Senior Lecturer, UNSW; Owner and Director, Health Technology Analysts, University of Sydney

It’s hard to test therapies for rare cancers because there are too few people to study. from www.shutterstock.com.au

October 2, 2017

How we can overcome the lack of treatment options for rare cancers

Colman Taylor, University of Sydney and John Zalcberg, Monash University

Rare cancers are hard to research given the few patients that have each type of cancer, so how can we improve treatment for these patients?

Consumers want to know if their complementary medicines are safe and effective. But are links between science and manufacturers the answer? from www.shutterstock.com.au

October 27, 2016

What will consumers gain from research into complementary medicines?

Nick Fuller, University of Sydney and Colman Taylor, University of Sydney

A new multimillion dollar deal between Swisse Wellness and CSIRO has raised questions about the integrity of Australia’s premier scientific research organisation and the motivations behind the deal.

Contact Colman for

General
Media request
Speaking request
Consulting / Advising
Research collaboration
Research supervision

Location: Sydney, Australia
Website
X (formerly Twitter): @colmantaylor
Article Feed
Joined October 27, 2016